In conclusion, this cost-effectiveness study indicates that first-line treatment of ALK+ NSCLC with alectinib provides superior clinical outcomes to crizotinib and is cost-effective for the French Health care system. The gene discussed is ALK; the disease is non-small cell lung carcinoma.